Theracryf Plc

LSE (GBp): Theracryf Plc (TCF)

Last Price

0.22

Today's Change

+0.01 (4.76%)

Day's Change

0.22 - 0.22

Trading Volume

21,495

Profile
TCF

Exchange:  London Stock Exchange London Stock Exchange

Currency:  GBp GBp

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Huw Jones BSc, Huw Jones BSc,

Full Time Employees:  9 9

IPO Date:  2015-10-21 2015-10-21

CIK: 

ISIN:  GB00BSVYN304 GB00BSVYN304

CUSIP: 

Beta:  1.50 1.50

Last Dividend:  0.00 0.00

Dcf Diff:  -0.18 -0.18

Dcf:  0.39 0.39

Description

Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders. The company's lead product is SFX-01 that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase I clinical trials for the treatment of neurodevelopmental disorders and glioblastoma, as well as in preclinical stage for the treatment of rhabdomyosarcoma. In addition, it engages in the development of orexin 1 antagonist, which is in late preclinical stage targeting addiction and anxiety; and atypical dopamine transporter inhibitor (DAT), which is in late preclinical stage targeting fatigue and narcolepsy. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.

Address

Alderley Park,
Nether Alderley, SK10 4TG, GB

44 1625 315 090

http://theracryf.com

Discussions
Be the first to like this. Showing 0 of 0 comments

{uid}

{comment}

Just now

Post a Comment